EULAR SSc Recommendations Now Include Immunosuppressants

The update to 2017 recommendations include targeted synthetic and biologic disease-modifying antirheumatic drugs for the first time.

Related Keywords

Milan ,Lombardia ,Italy ,Ariane Herrick ,European Alliance Of Associations ,European Congress ,Astrazeneca ,Mitsubishi ,University Of Manchester England ,Glaxosmithkline ,Boehringer Ingelheim ,European Alliance ,Del Galdo ,Leeds Teaching Hospital ,Scleroderma Trials ,Scleroderma ,Crest Syndrome ,Biologic Therapy ,Pulmonary Hypertension ,Systemic Sclerosis ,Diffuse Scleroderma ,Interstitial Lung Disease ,Lung ,Heart Failure ,Lung Fibrosis ,Pulmonary Fibrosis ,Ibrosis Pulmonary ,Monoclonal Antibody ,Etuximab ,Ituximab ,Hypertension ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,U11248 ,Unitinib ,Rastuzumab ,Europe ,